arrow_back Back to App

Cheaper Medicines: Patent Dispute Changes for Biologic Products.

New rules aim to simplify the market entry of more affordable versions of biologic drugs, potentially lowering their prices. The act limits the number of patents pharmaceutical companies can use in legal disputes, speeding up access to generic equivalents. This could mean easier access to necessary medications and potentially lower healthcare costs for citizens.
Key points
Limits the number of patents that can be asserted in legal disputes over biologic drugs, aiming to accelerate the introduction of cheaper alternatives.
Allows for an increase in the number of patents in a dispute only under specific justified circumstances, such as when a generic company fails to provide required information.
These provisions apply to applications for biologic drug approval submitted after the act's enactment, impacting future medications.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2884
Sponsor: Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]
Process start date: 2021-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2884.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Limits the number of patents that can be asserted in legal disputes over biologic drugs, aiming to accelerate the introduction of cheaper alternatives.
  • Allows for an increase in the number of patents in a dispute only under specific justified circumstances, such as when a generic company fails to provide required information.
  • These provisions apply to applications for biologic drug approval submitted after the act's enactment, impacting future medications.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4].

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by Voice Vote.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Courts and Law Economy